RxDoctor Payments Data

David Holmes, MD

Cardiovascular Disease · Opelika, ALNPI 1467489286

Payments from drug & device makers

$12,447in general payments, 2019–2025

Across 461 payments — averaging $27.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • Actelion Pharmaceuticals US, Inc.$1K
  • Amgen$1K
  • Elutia, Inc.$786
  • Amarin Pharma, Inc.$707
  • AstraZeneca$575
  • plus $6K from 39 others

What the payments were for

  • Food & beverage$12,26799%
  • Education$380%
  • Entertainment$1411%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,447 in reported general payments places this provider in the 75th percentile of 292 cardiovascular disease providers in Alabama.

See all cardiovascular disease providers in Alabama

Medicare billing

Part B allowed, 2024
$484,016
Medicare patients
1,329
Services billed
5,460

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AdempasRiociguat61$900,504
OpsumitMacitentan47$772,714
EliquisApixaban610$522,107
EntrestoSacubitril/Valsartan213$168,559
Repatha SureclickEvolocumab232$152,320
XareltoRivaroxaban165$146,331
BrilintaTicagrelor85$60,914
FarxigaDapagliflozin Propanediol71$54,196
MultaqDronedarone Hcl21$22,244
Praluent PenAlirocumab42$21,671
Ranolazine ErRanolazine121$11,500
Atorvastatin Calcium606$9,085
VascepaIcosapent Ethyl14$7,386
Tadalafil15$6,841
SotalolSotalol Hcl190$5,885

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BayerAdempas$169$900,50461 claims
Actelion Pharmaceuticals US, Inc.Opsumit$1,129$772,71447 claims
PfizerEliquis$257$522,107610 claims
NovartisEntresto$367$168,559213 claims
Johnson & JohnsonXarelto$478$146,331165 claims
AstraZenecaBrilinta, Farxiga$575$115,110156 claims
Sanofi-aventis U.S. LLCMultaq$183$22,24421 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 292 cardiovascular disease providers in Alabama.

Other cardiovascular disease in Opelika

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →